Therapy Directory

Semaglutide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Semaglutide as a study intervention. Browse Semaglutide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Aug 28, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

103

Shown on this page

Local indexed summaries

103

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for Semaglutide. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 103 matching trials for Semaglutide.

Indexed local directory records.

Top conditions

Obesity 36 Diabetes Mellitus, Type 2 10 Overweight 10 Type 2 Diabetes 8 Alcohol Use Disorder 3 HIV 3

Top sponsors

Novo Nordisk A/S 25 University of Colorado, Denver 5 Yale University 5 Brigham and Women's Hospital 4 Mayo Clinic 4 The University of Texas Health Science Center, Houston 4

Top locations

Dallas, Texas 20 Houston, Texas 19 San Antonio, Texas 17 Philadelphia, Pennsylvania 13 Nashville, Tennessee 12 Aurora, Colorado 11

Indexed official records

Open in full search

Conditions: Obesity, Overweight
Interventions: Placebo, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Escondido, California • Huntington Park, California + 13 more

Conditions: Chemically-Induced Disorders, Mental Disorder, Narcotic-Related Disorders, Opioid, Opioid Abuse and Addiction, Opioid Use Disorder, Substance-Related Disorders
Interventions: Placebo, Semaglutide Pen Injector; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more

Conditions: Obesity & Overweight
Interventions: Placebo liquid emulsion formulation, Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet; Drug
Lead sponsor: Gila Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Type 2, Obesity
Interventions: Semaglutide Pen Injector [Ozempic]; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 89 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Semaglutide Placebo, UBT251, UBT251 Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Fountain Valley, California • Long Beach, California + 21 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Semaglutide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 63
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Obesity
Interventions: NNC0662-0419, NNC0662-0419 Placebo, Semaglutide, Semaglutide placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Montgomery, Alabama • Costa Mesa, California • Los Angeles, California + 20 more

Conditions: Overweight and/or Obesity
Interventions: VX-201, semaglutide SC; Combination Product · Drug
Lead sponsor: Terrestrial Bio, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alzheimer Dementia (AD)
Interventions: IL-2 (Aldesleukin), Placebo, Semaglutide Plus IL-2; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 50 Years to 86 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Overweight
Interventions: Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 35,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Methamphetamine-dependence
Interventions: Placebo, Semaglutide; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Interventions: Placebo, Semaglutide; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Aurora, Colorado • Seattle, Washington • Spokane, Washington

About this Semaglutide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Semaglutide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Semaglutide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Semaglutide clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

GLP-1R Agonist Treatment for Opioid Use Disorder

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

Pharmacogenetics of Response to GLP1R Agonists

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

Weight Loss in Adults Using Semaglutide (Real-world Study)

Glutide for Ending Methamphetamine

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

About this Semaglutide clinical trials directory page